Treats relapsing forms of multiple sclerosis (MS). ANDA 209700, held by Teva Pharms USA. Teriflunomide.
As of Nov 16, 2026, ANDA 209700 (Teriflunomide), held by Teva Pharms USA, was first approved by FDA on Sep 4, 2018, with 3 approved supplements and 0 published complete response letters.
Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 4, 2018 | Original application | Approved | None posted |
| Teriflunomide7MG · tablet;oral | Teriflunomide | Rx |
| Teriflunomide14MG · tablet;oral | Teriflunomide | Rx |
| Mar 13, 2025 | Supplement 7Labeling · Standard review | Approved | None posted |
| Feb 20, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jul 15, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 4, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters